Published: 2016-12-27

Expression of Bcl-2 marker in premalignant lesions of cervical cancer

Shreedevi Kamaraddi, Ashwini Nayak U., Shridhar Honnappa, Asha Swarup


Background: Cervical cancer is one of the most common gynecological cancers in women of developing countries. HPV DNA testing is preferred cervical screening method for woman 30-65 years old as HPV is the proved causative agent of cervical carcinoma. Due to the high costs involved in doing HPV DNA test there is a need for a biomarker such as Bcl-2 which can indicate the initiation of carcinogenic process of HPV infection and thus can be used to identify those woman who will need more surveillance.

Methods: Specimens of cervical biopsy retrieved from incident cases for routine histopathological evaluation from the Department of Obstetrics and gynecology, M.S. Ramaiah hospital, Bangalore, India from March 2013 to September 2015 formed the source of data for the study.

Results: In this study total of 46 cases were studied which included 9 cases of CIN-1, 8 cases of CIN-2, 7 cases of CIN-3, 12 cases of squamous cell carcinoma and 10 cases of on specific cervicitis. Higher number of malignant lesions (75%) expressed Bcl-2 positivity as compared to premalignant lesions (62.5%). In case of CIN lesions, Bcl-2 positivity increased as the grade increased (CIN-1- 55.56%; CIN-2 - 62.5%; CIN-3 -71.43%).

Conclusions: Bcl-2 which is an intracellular membrane protein which prevents apoptotic cell death can be used as a biomarker to know the severity of the CIN lesion and hence help in identifying the high risk CIN lesions which need further surveillance and treatment.


Cervical cancer, Screening, Biomarker

Full Text:



Report-ICO Information Centre on HPV and Cancer.

Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer cervix in India Indian J Med Res. 2009;130:219-21.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan. 2008.

Kurvinen K, Syrjänen K, Syrjänen S. p53 and bcl-2 proteins as prognostic markers in human papillomavirus-associated cervical lesions. J ClinOncol. 1996;14:2120-30.

Aletra C, Ravazoula P, Scopa C, Kounelis S, Sotiropoulou G, Kourounis G. Expression of bcl-2 and bax in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Eur J GynaecolOncol. 2000;21:494-8.

Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol. 2000;77:129-36.

Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalekshmi TN, Nair MK et al. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol Biomarkers Prev. 1996;5(5):329-35.

Shukla S, Dass J, Pujani M. p53 and bcl2 expression in malignant and premalignant lesions of uterine cervix and their correlation with human papilloma virus 16 and 18. 2014.

Guimarães MC, Gonçalves MA, Soares CP, Bettini JS, Duarte RA, Soares EG. Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions. J Histochem Cytochem. 2005;53(4):509-16.

Brychtova S, Brychta T, Kotrsova L, Pilka R, Tichy M, Ticha V et al. Expression of bcl-2 in dysplastic and neoplastic cervical lesions in relation to cell proliferation and HPV infection. Neoplasma. 2000;47:143-7.

Nair P, Nair KM, Jayaprakash PG, Radhakrishna MP. Decreased programmed cell death in the uterine cervix associated with high risk human papilloma virus infection. PatholOncol Res. 1999;5:95-103.

Takano SM, Hashimura Y, Shoji MY. Okayasu I. The possible role of bcl-2 expression in the progression of tumors of the uterine cervix. Cancer. 1995;76(2):297-303.

Grace VM, Shalini JV, lekha TT, Devaraj SN, Devaraj H. co-overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 2003;91:51-8.